Johnson & Johnson

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. 

CEO
Joaquin Duato
CEOJoaquin Duato
Employees
140,800
Employees140,800
Headquarters
New Brunswick, New Jersey
HeadquartersNew Brunswick, New Jersey
Founded
1887
Founded1887
Employees
140,800
Employees140,800

JNJ Key Statistics

Market cap
542.20B
Market cap542.20B
Price-Earnings ratio
26.05
Price-Earnings ratio26.05
Dividend yield
2.31%
Dividend yield2.31%
Average volume
8.36M
Average volume8.36M
High today
$232.00
High today$232.00
Low today
$224.59
Low today$224.59
Open price
$230.88
Open price$230.88
Volume
13.90M
Volume13.90M
52 Week high
$251.71
52 Week high$251.71
52 Week low
$149.04
52 Week low$149.04

Stock Snapshot

The current Johnson & Johnson(JNJ) stock price is $225.46, with a market capitalization of 542.2B. The stock trades at a price-to-earnings (P/E) ratio of 26.05 and offers a dividend yield of 2.3%.

During the trading session on 2026-05-30, Johnson & Johnson(JNJ) shares reached a daily high of $232.00 and a low of $224.59. At a current price of $225.46, the stock is +0.4% higher than the low and still -2.8% under the high.

Trading volume for Johnson & Johnson(JNJ) stock has reached 13.9M, versus its average volume of 8.36M.

Over the past 52 weeks, Johnson & Johnson(JNJ) stock has traded between a high of $251.71 and a low of $149.04.

Over the past 52 weeks, Johnson & Johnson(JNJ) stock has traded between a high of $251.71 and a low of $149.04.

JNJ News

Nasdaq 5h
How to Recession-Proof Your Retirement Income Before Summer 2026

Key Points Recessions are a normal part of the economic cycle and can't be avoided. Investors can prepare for recessions by focusing on resilient sectors like...

How to Recession-Proof Your Retirement Income Before Summer 2026
24/7 Wall St. 5h
The Two Bucket Income Portfolio That Pays $5,000 a Month Plus a Cash Reserve to Survive 2008 Style Drawdowns

The Two Bucket Income Portfolio That Pays $5,000 a Month Plus a Cash Reserve to Survive 2008 Style Drawdowns By Drew Wood Published May 30, 9:18AM EDT Quick R...

The Two Bucket Income Portfolio That Pays $5,000 a Month Plus a Cash Reserve to Survive 2008 Style Drawdowns
Axios 24h
Mike Johnson faces brutal June as deadlines come due - Axios

...

Mike Johnson faces brutal June as deadlines come due - Axios

Analyst ratings

65%

of 26 ratings
Buy
65.4%
Hold
26.9%
Sell
7.7%

More JNJ News

TipRanks 1d
J&J reports updated results from Phase 1/1b CHRYSALIS-2 study

Johnson & Johnson announced updated results from the Phase 1/1b CHRYSALIS-2 study evaluating intravenous RYBREVANT in combination with LAZCLUZE in patients with...

TipRanks 1d
Johnson & Johnson reports new data from Phase 3 MajesTEC-9 study

Johnson & Johnson announced new data from the Phase 3 MajesTEC-9 study demonstrating clinically meaningful and statistically significant improvements in progres...

Simply Wall St 2d
Johnson And Johnson MedTech Moves And What They Could Mean For Investors

Johnson & Johnson subsidiaries are integrating Gemtrack radiofrequency tracking technology from MinMaxMedical into DePuy Synthes orthopedic products. The compa...

Johnson And Johnson MedTech Moves And What They Could Mean For Investors
TipRanks 2d
J&J says FDA approves Tremfya label expansion

Johnson & Johnson announced that the U.S. Food and Drug Administration has approved a supplemental Biologics License Application to include evidence in the TREM...

Nasdaq 2d
J&J Stock Gains Nearly 12% Year to Date: Buy, Sell or Hold Now?

Johnson & Johnson’s JNJ stock has risen 11.8% so far this year. One of the biggest drivers of the increase was J&J’s robust first-quarter 2026 results, as it be...

J&J Stock Gains Nearly 12% Year to Date: Buy, Sell or Hold Now?
The Wall Street Journal 2d
J&J Mastered Cancer Biotech Deals on the Cheap. Can It Stay on the Cutting Edge?

Using tie-ups has long rewarded J&J, but it sometimes creates awkward situations. Chen Haoming / Zuma Press Johnson & Johnson JNJ 0.48 %increase; green up poin...

J&J Mastered Cancer Biotech Deals on the Cheap. Can It Stay on the Cutting Edge?
Nasdaq 4d
President Trump's Drug Pricing Policies Could Hurt Drugmakers' Profits. Time to Sell Pharma Stocks?

Key Points Trump is looking to lower prescription drug prices in ways that could harm the profits of drugmakers in the U.S. Even if that happens, diversified...

President Trump's Drug Pricing Policies Could Hurt Drugmakers' Profits. Time to Sell Pharma Stocks?

People also own

Based on the portfolios of people who own JNJ. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.